Resources

6,000 pharmacy professionals attended Asembia this year. What were the key takeaways from the conference?

Register for Truveris’ exclusive Human Resources round table on June 8th, 2022.

Plan sponsors are looking for new ways to contain specialty costs. How should they evaluate new copay assistance strategies?

Truveris covers exactly how leading employer groups and their brokers are implementing copay maximizers and accumulators.

As pharmacy costs increase, what are strategies plan sponsors can take to control specialty pharmacy spend?

Read Sally Welborn’s POV piece on the misaligned incentives at play in the pharmacy benefits ecosystem – and what it means for plan sponsors.

With so much importance placed on the launch of a new drug, how should pharma brands ensure a successful launch?  

How are copay maximizers and alternative funding impacting plans – and members? Watch our on-demand webinar to learn more.

Truveris announces the launch of oneRx, the only drug price transparency solution that helps members navigate their pharmacy benefits.

After you procure a strong PBM contract, make sure your members are engaging with the plan productively.

See how Truveris has helped employers of all sizes procure their pharmacy benefits.

By framing your pharmacy benefits strategy around these three pillars, you’ll construct a more cost-effective, accessible pharmacy program.

The State of Minnesota has selected Truveris as its exclusive pharmacy benefits procurement and oversight partner for 52,000 employees.

With Delta and Omicron, the COVID-19 pandemic carries on. How are these variants impacting pharma brands?

While a pharmacy benefits contract is a powerful lever for managing spend, it is also very complicated, with variables impacted by market and industry dynamics.

Many brands experience a drop in claims during January. What strategies successfully drive adherence during the beginning of the year?

What is member-centricity and why should plan sponsors and brokers strive to reimagine their pharmacy program with members in mind?

Watch the recording of our webinar and Q&A, led by Clinical Director Adrienne Trudell (PharmD, BCGP, CPBS), with strategies to proactively manage your pharmacy benefits contract.

Four core themes from Asembia 2021 that will drive dialogue in the specialty pharmacy ecosystem in 2022 – and beyond.

340B is increasingly a part of the pharmacy conversation. How should stakeholders react to the program?

Truveris’ Life Sciences data science team conducted a deep-dive analysis to assess the impact of COVID-19 on prescribing and claim volume throughout an 18-month span.

Given the burgeoning pipeline of new cell and gene therapies, plan sponsors must understand the clinical, operational, & financial implications of these innovations.

Listen to Episode 26 of Employers Health’s HR Benecast, featuring a full-length conversation with Truveris CEO, Nanette Oddo.

Truveris announced today that Nanette Oddo, formerly Truveris’ Chief Strategy Officer, has been named President and Chief Executive Officer.

Loss of exclusivity can feel like a dramatic shift, forever changing a drug’s profitability. However, this doesn’t have to be your brand’s fate.

Recently, several states have passed legislation that prohibits the use of copay accumulator adjustment programs. How does this affect your organization?

Understanding the ins and outs of drug formularies is essential to making an informed decision on which PBM to select for your members.

Generic versions of brand name medications are not all the same. Understanding their differences and the MAC pricing implications is critical for choosing the most cost-effective PBM.

Watch Truveris’ on-demand webinar outlining how Payers can best anticipate and manage new gene therapies.

Looking forward to the future of pharmacy, it’s critical to understand how a specialty drug is defined, how it differs from traditional, non-specialty drugs, and how specialty is impacting employers’ benefit plan designs.  

Many Medicare patients end up not filling their high-cost prescriptions due to the Medicare coverage gap. What can manufacturers do to help Medicare patients stay adherent? 

Watch Truveris’ webinar to learn more about how you can better manage a self-funded specialty pharmacy program.

Using simple patient inputs to provide a customized view of specific coverage restrictions and out-of-pocket cost obligations, real-time benefits checks empower patients and providers to make informed decisions about care.

Adopting these three approaches can help manufacturers to build a more effective affordability program. 

Pharmacy Benefits Managers, also referred to as PBMs, are, in essence, the intermediaries of almost every aspect of the pharmacy benefits marketplace.

Do you know how much your company spends on pharmacy benefits? If you don’t, you’re not alone.

It’s not uncommon for employers to be confused with all the industry-speak and confusing jargon that surrounds the work of pharmacy-benefit managers (PBMs

Under the leadership of CEO Jeff Eberle, Truveris has assembled a seasoned team of industry veterans to drive innovation and fuel the Company’s rapid growth trajectory.

You likely already know what patient abandonment is: when a prescription is written by a doctor but never picked up at the pharmacy.

While the goals of every copay program vary, the top 5 essential ROI metrics to track its success stay the same.

Before signing up for any new insurance plan, you should familiarize yourself with an often overlooked segment of insurance — your pharmacy benefits plan.

In October of 2017, Anthem Inc. announced its launching of IngenioRx, an in-house pharmacy benefits manager (PBM).